A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis
extracts which has high affinity on a series of receptors, including Type 1 cannabinoid …
extracts which has high affinity on a series of receptors, including Type 1 cannabinoid …
Cannabidiol adverse effects and toxicity
MA Huestis, R Solimini, S Pichini… - Current …, 2019 - ingentaconnect.com
Background: Currently, there is a great interest in the potential medical use of cannabidiol
(CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD …
(CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD …
Cannabidiol: State of the art and new challenges for therapeutic applications
Over the past years, several lines of evidence support a therapeutic potential of Cannabis
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …
Immune responses regulated by cannabidiol
JM Nichols, BLF Kaplan - Cannabis and cannabinoid research, 2020 - liebertpub.com
Introduction: Cannabidiol (CBD) as Epidiolex®(GW Pharmaceuticals) was recently
approved by the US Food and Drug Administration (FDA) to treat rare forms of epilepsy in …
approved by the US Food and Drug Administration (FDA) to treat rare forms of epilepsy in …
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
S Burstein - Bioorganic & medicinal chemistry, 2015 - Elsevier
First isolated from Cannabis in 1940 by Roger Adams, the structure of CBD was not
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
To present a summary of current scientific evidence about the cannabinoid, cannabidiol
(CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders …
(CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders …
[HTML][HTML] The molecular activity of cannabidiol in the regulation of Nrf2 system interacting with NF-κB pathway under oxidative stress
SA Ekiner, A Gęgotek, E Skrzydlewska - Redox Biology, 2022 - Elsevier
Cannabidiol (CBD), the major non-psychoactive phytocannabinoid of Cannabis sativa L., is
one of the most studied compounds in pharmacotherapeutic approaches to treat oxidative …
one of the most studied compounds in pharmacotherapeutic approaches to treat oxidative …
Safety and side effects of cannabidiol, a Cannabis sativa constituent
M Machado Bergamaschi… - Current drug …, 2011 - ingentaconnect.com
Cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, has multiple
pharmacological actions, including anxiolytic, antipsychotic, antiemetic and anti …
pharmacological actions, including anxiolytic, antipsychotic, antiemetic and anti …
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Δ 9-tetrahydrocannabinol binds cannabinoid (CB 1 and CB 2) receptors, which are activated
by endogenous compounds (endocannabinoids) and are involved in a wide range of …
by endogenous compounds (endocannabinoids) and are involved in a wide range of …
Molecular and cellular mechanisms of action of cannabidiol
Cannabidiol (CBD) is the primary non-psychoactive chemical from Cannabis Sativa, a plant
used for centuries for both recreational and medicinal purposes. CBD lacks the psychotropic …
used for centuries for both recreational and medicinal purposes. CBD lacks the psychotropic …